The fixed combination of the drugs dapagliflozin and metformin (Xigduo) has been approved since January 2014 for adults with type 2 diabetes in whom diet and exercise do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the IQWiG now examined whether this new drug combination offers an added benefit over the appropriate comparator therapy. No such added benefit can be derived from the dossier, however, because the drug manufacturer did not present any suitable data for any of the possible therapeutic indications.

For more details, go to: https://www.iqwig.de/en/press/press_releases/press_releases/added_benefit_of_the_fixed_combination_of_dapagliflozin_and_metformin_is_not_proven.6109.html